E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Lumbosacral Radicular Syndrome |
Lumbosacraal radiculair syndroom |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Nervous System Diseases [C10] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10037739 |
E.1.2 | Term | R sciatica |
E.1.2 | System Organ Class | 100000014640 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective of this study is to assess the effectiveness and cost-effectiveness in terms of the number of surgeries prevented of a combination therapy versus usual care. |
De primaire doelstelling van dit onderzoek is om de effectiviteit en de kosteneffectiviteit in termen van het aantal voorkomen operaties te bepalen van een combinatietherapie in vergelijking met gebruikelijke zorg. |
|
E.2.2 | Secondary objectives of the trial |
The secondary objective of this study is to assess the effectiveness and cost-effectiveness in terms of pain (leg and back), functioning, self-perceived recovery and health-related quality of life of a combination therapy versus usual care. |
De secundaire doelstelling van dit onderzoek is om de effectiviteit en de kosteneffectiviteit in termen van pijn, functioneren, ervaren herstel, en kwaliteit van leven te bepalen van een combinatietherapie in vergelijking met gebruikelijke zorg. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
In order to be eligible to participate in this study, a subject must meet all of the following criteria:
• Incapacitating lumbosacral radicular syndrome with leg pain (with or without back pain) that had lasted for a minimum of 6 weeks
with or without mild neurological deficit (MRC higher than 3)
• MRI which confirms a lumbar HNP that compromises the spinal nerve and can explain the clinical symptoms of the patient
• The patients should according to usual care have an indication for lumbar HNP operation by a neurosurgeon.
• Signed informed consent for participation in the study
• 18 years and |
Om in aanmerking te komen voor deelname aan dit onderzoek, moet een patient aan de volgende criteria voldoen:
• Invaliderende lumbosacraal radiculair syndroom met pijn in de benen (met of zonder rugpijn), met een duur van minimaal 6
weken, met of zonder milde neurologische uitval (MRC groter dan 3)
• MRI laat een lumbale HNP zien die de spinale zenuwen bekneld en de klinische symptomen van de patiënt kan verklaren
• De patiënt moet volgens de “gebruikelijke zorg" in aanmerking komen voor neurochirurgische behandeling van de lumbale HNP.
•Informed consent
•18 jaar en ouder |
|
E.4 | Principal exclusion criteria |
A potentially eligible subject who meets any of the following criteria will be excluded from participation in this study:
• Patients exclude suffering from cauda equina syndrome
• Previous spine surgery at the same level during the previous 6 months
• Previous transforminal injections at the same level during the previous 6 months
• Bony stenosis
• Spondylolisthesis
• Pregnancy
• Complicated disc herniation requiring more operations
• Severe coexisting disease e.g. osteoporosis, dementia
• Patient with contra-indications for steroids injections
• Insufficient knowledge of the Dutch language
• Emergency surgery as determined by the neurosurgeon
• Severe paresis MRC less than or equal to 3
• Being allergic for OMNIPAQUE 240 |
Exclusiecriteria zijn:
• Patiënten met caudasyndroom of stenose of spondylolisthesis
• Vorige chirurgie van de wervelkolom op hetzelfde niveau in de voorgaande 6 maanden
• Vorige transforminal injecties op hetzelfde niveau gedurende de 6 maanden
• Zwangerschap
• Gecompliceerde hernia
• Ernstige ziekte, bijvoorbeeld osteoporose, dementie
• Patiënt met contra-indicaties voor steroïden injecties
• Onvoldoende kennis van de Nederlandse taal
• Spoedoperatie zoals bepaald door de neurochirurg
• Ernstige parese MRC kleiner dan of gelijk aan 3
• Allergie voor het contrast medium OMNIPAQUE 240 |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Surgery rate (number of patients undergoing surgery during a 12-month follow-up) |
Herniaoperaties (aantal patiënten dat gedurende de follow-up periode een herniaoperatie ondergaat) |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Baseline and 2, 4, 6, 9 and 12 months |
Baseline en 2, 4, 6, 9 and 12 maanden |
|
E.5.2 | Secondary end point(s) |
Back and leg pain intensity (NPRS), physical functioning (RMDQ-23), self-perceived recovery (GPE), health-related quality of life (EQ-5D-5L) en societal costs. |
Rug- en beenpijn (NPRS), functioneren (RMDQ-23), ervaren herstel (GPE), kwaliteit van leven (EQ-5D-5L) en maatschappelijke kosten. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Baseline, 4 weeks (only for pain), and 2, 4, 6, 9 and 12 months |
Baseline, 4 weken (enkel pijn) en 2, 4, 6, 9 and 12 maanden |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
Cost-effectiveness analysis / Health Technology Assessment |
Kosteneffectiviteit / Doelmatigheidsonderzoek |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
Gebruikelijke zorg |
Usual care |
|
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 6 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
146 patients will be included. After the last inclusion, 12 months are required for follow-up. |
146 patienten worden geincludeerd. Na de laatste inclusie is nog een jaar follow-up nodig. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | |